CRISPR-based knockout screening identifies the loss of MIEF2 to enhance oxaliplatin resistance in colorectal cancer through inhibiting the mitochondrial apoptosis pathway

The first-line anticancer agent oxaliplatin (OXL) is the preferred drug for treating colorectal cancer (CRC); however, the development of drug resistance is common in patients treated with OXL, which considerably reduces the efficacy of OXL-based regimens. By performing genome-wide CRISPR/Cas9 libra...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Chaozheng, Li, Kang, Li, Ya, Peng, Xudong, Teng, Biyun, He, Kuan, Jin, Aishun, Wang, Wang, Wei, Zhengqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465453/
https://www.ncbi.nlm.nih.gov/pubmed/36106106
http://dx.doi.org/10.3389/fonc.2022.881487

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465453/
https://www.ncbi.nlm.nih.gov/pubmed/36106106
http://dx.doi.org/10.3389/fonc.2022.881487

Ejemplares similares